FDA Sets October 28 Meeting on Rare Disease Drug Framework

Rare Disease Families Can Weigh In on FDA Drug Framework at October 28 Meeting and Through December 11

FDA will hear from rare disease families at an Oct. 28 hybrid meeting, with comments open until Dec. 11. Here is how to register and comment.

FDA ‘reset’ continues with new plan for reviewing rare disease drugs

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

FDA unveils rare disease initiative to enhance therapy development

The FDA’s Rare Disease Framework aims to speed rare disease drug development using flexible evidence standards. Read more here.

FDA sets October 28 meeting on rare disease drug framework

WASHINGTON — The Food and Drug Administration announced it launched the Rare Disease Framework Initiative to reshape how drugs and biologics for rare diseases are developed.The agency said the effort aimed to build a framework that fits the realities of…

New FDA framework favors consistency over flexibility on rare disease drugs

Then-acting FDA leaders said over the summer that regulatory flexibility wasn't the standard they were striving for when the agency gauges rare disease drugs. Now, a more consistent system for assessing

FDA Launches Rare Disease Framework Initiative

FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.